Introduction/Background Low-dose rate brachytherapy has some radiobiological advantages compared to external beam radiotherapy: subletal damages repair during irradiation leading to a relative protection of healthy tissues; no Tumor cell repopulation, cell cycle redistribution and a low oxygen enhancement ratio.

Methodology This is a retrospective eight-year study from June 10, 2010 to April 16, 2019. This study was of interest to all Admitted patients after multidisciplinary consultation meeting for gynecological cancer (cervical or endometrial cancer). Ayant bénéficié d’une r curiethérapie à bas de début de dose vaginale ou intra-cavitaire.

Results We collected 185 patients, with an average age of 45 years. The patients were spread between Martinique and the the other Carribean islands. Cervical cancer was more common. The predominant stage was stage IIA for cervical cancer and stage III for endometrial cancer. The dose of 30Gy was delivered in 3 days for uterovaginal brachytherapy after radiotherapy-chemotherapy combination, 60Gy in exclusive vaginal brachytherapy and 15Gy in barrier brachytherapy.

Conclusion Brachytherapy retains a key role in the treatment of gynecological cancers. A better knowledge of the dose and its distributions makes it possible to hope for an improvement in the rate of local control and a significant decrease in complications.

Disclosure Nothing to disclose.